Compare Stryker Corporation (SYK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs TG Therapeutics Inc — how do they compare? Stryker Corporation trades at $319.04 (market cap $122.35B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: Stryker Corporation is far larger — about 14.8× TG Therapeutics Inc's market cap, and Stryker Corporation pays a 1% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SYK | TGTX | |
|---|---|---|
Market Cap | $122.35B | $8.26B |
Sector | Technology | Health |
52-Week High | $403.53 | $59.06 |
52-Week Low | $282.58 | $26.39 |
Enterprise Value | $134.10B | $8.50B |
Dividend Yield | 1% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
